Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Internal Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
Semin Respir Crit Care Med. 2010 Apr;31(2):189-207. doi: 10.1055/s-0030-1249116. Epub 2010 Mar 30.
Lung transplantation is a therapeutic option for patients with end-stage pulmonary disorders. Unfortunately, chronic lung allograft rejection, in the form of obliterative bronchiolitis and its clinical correlate bronchiolitis obliterans syndrome (BOS), continues to be highly prevalent and is the major limitation to long-term survival. The pathogenesis of BOS is complex and involves alloimmune and nonalloimmune pathways. The airway obstruction involved is classically progressive and unresponsive to treatment; however, the course is highly variable, and distinguishable phenotypes may exist. A better understanding of the risk factors and their relationship to the pathological mechanisms of chronic lung allograft rejection should lead to better pharmacological targets to prevent or treat this syndrome.
肺移植是治疗终末期肺部疾病患者的一种选择。不幸的是，以闭塞性细支气管炎及其临床相关的闭塞性细支气管炎综合征（BOS）形式出现的慢性肺移植物排斥反应仍然非常普遍，是长期存活的主要限制因素。BOS 的发病机制复杂，涉及同种免疫和非同种免疫途径。所涉及的气道阻塞通常是进行性的，对治疗无反应；然而，病程高度可变，可能存在可区分的表型。更好地了解危险因素及其与慢性肺移植物排斥的病理机制的关系，应能为预防或治疗这种综合征提供更好的药物靶点。
